Miscellaneous CBP Releases
CBP issued the following releases on commercial trade and related matters:
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
- CBP informed the trade that on Dec. 16, there is now expanded user access to the ACH Refund Authorization tab under the Importer sub-account view (here).
- CBP officers in Cincinnati, special agents with the FDA's Office of Criminal Investigation and consumer safety officers with FDA's Office of Import Operations conducted a late October operation in which they intercepted high-risk, FDA-regulated ophthalmology products and misbranded prescription pharmaceuticals, such as orthopedic injections, rheumatology infusions, cosmetic devices, and oncology drugs, destined to locations in the U.S. Officers seized 398 shipments containing 8,521 pairs of undeclared or misdeclared contact lenses. Officers also seized 50 other shipments containing misbranded or misdeclared FDA-regulated drugs or medical devices, such as GLP1 medications, Botox, dermal fillers, skin care products, and several other FDA-prohibited substances and powders, CBP said. The cumulative manufacturer’s suggested retail price for the prohibited pharmaceuticals was $407,784, had they been legally imported, the agency said (here).